Taken together, the results of in vivo efficacy studies on cell-line xenograft tumor models with different FGFR aberrations show that CPL304110 exhibits a potent broad spectrum of antitumor activity against FGFR1, 2, and 3, which represent different types of tumor histology in the clinical setting. This evidence concerns the gene FGFR1 and neoplasm.